Corona Remedies share price today

Corona Remedies Ltd's share price was ₹2,441.10 at the close on 6 November 2026. It has been rising for 38 weeks. That is 28.9% above its average price over the last 200 trading days. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 3 weeks in a row.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Corona Remedies Ltd is in stage 2. The phase helps read everything below.

Since its first close in our records, on 19 December 2025, it has traded between ₹1,348 and ₹2,441, and at that close it was at the high of that range.

Over the last 11 months the share price moved +78% while the NIFTY 500 moved −8%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: indian funds and insurers (DIIs) raised their stake for 3 quarters in a row, foreign funds (FIIs) raised their stake for 3 quarters in a row and revenue up on a year earlier for 5 quarters in a row (every quarter we can compare).

1. Indian funds and insurers (DIIs) raised their stake for 3 quarters in a row

   From 6.8% to 16.4% of the company by the September 2026 quarter.

2. Foreign funds (FIIs) raised their stake for 3 quarters in a row

   From 1.8% to 4.2% of the company by the September 2026 quarter.

3. Revenue up on a year earlier for 5 quarters in a row (every quarter we can compare)

   In the September 2026 quarter revenue was ₹441 crore, +22.2% on a year earlier.

For July to September 2026 (the quarter ended 30 September 2026), Corona Remedies reported revenue of ₹441 crore, up 22.2% from ₹361 crore a year earlier, and a profit of ₹60.0 crore, up 15.4% from ₹52.0 crore.

Corona Remedies results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

The newest call in our records is from 3 August 2026, about April to June 2026; a call about these results is not in our records yet.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

Corona Remedies closed at ₹2,441.10 on 6 November 2026, up 77.6% from ₹1,374.30 a year earlier (19 December 2025). Its highest weekly close since December 2025 was ₹2,441.10 on 6 November 2026.

Corona Remedies share price: then and now

Weekly closing prices. Each change is the move from that price to the 6 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

54 weekly closes from 19 December 2025 to 6 November 2026.

6 Nov 2026: Corona Remedies closed at ₹2,441.10, up 13.6% on the week and up 20.6% on the month. Results for July to September 2026: Revenue up 22.2% and profit up 15.4% on a year earlier.

Earlier

• 3 Aug 2026: Corona Remedies held its results call for April to June 2026. Management guided: FY27 organic revenue growth 15.0% and profit growth 20.0%.
• 19 Jun 2026: ex-date for a dividend of ₹10 a share.

Corona Remedies paid ₹10 a share in regular dividends in the 12 months to 7 November 2026 (1 payment), a yield of 0.41% at the ₹2,441.10 close on 6 November 2026. The last was a dividend of ₹10 a share, ex-date 19 June 2026.

Corona Remedies dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here.

Yes. Corona Remedies Ltd paid out 33% of its profit as dividends in FY26, and it paid a dividend in each of its last 4 reported years.

From the NSE corporate-actions record, read 7 November 2026.

On the call for April to June 2026, held on 3 August 2026, Corona Remedies' management guided: FY27 organic revenue growth 15.0% and profit growth 20.0%.

“To strengthen our philosophy of "think hormone, think CORONA," which is somewhat complex in nature and where very few plants are focusing on hormones, the facility will help us in India as well, and it will also start gaining recognition in the international market.”Nirav Mehta, on the call for April to June 2026

What management guided

• FY27 inorganic revenue contribution of 1.5%-2.0%, resulting in about 17.0% total revenue growth.
• Wokadine portfolio growth 25.0% over the coming 3 years, doubling internal revenue from ₹20 crore to ₹40 crore.
• No FY27 medical-representative additions; thereafter additions of 6.0%-8.0% annually, approximately 200-250 people.
• Hormone facility asset turnover below 1.0 in FY27, moving through 2.0 toward 3.0 over the next 3 years; owned and outsourced manufacturing mix about 60.0%/40.0% in FY27.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 3 August 2026. The July to September 2026 results are out since, so this part may be out of date until we update it.

When Corona Remedies reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Raw-material pressure and gross-margin resilience - test whether cost offsets absorb the flagged geopolitical input shock.

Corona Remedies is on 3 of our India lists: Momentum stocks, Small & mid cap stocks and Pharma stocks.

Corona Remedies Ltd earned ₹60.0 Cr of net profit in the Sep 2026 quarter, +15.4% on the same quarter a year earlier. That is the 3rd quarter in a row of profit growth. Full-year FY26 profit was ₹185 Cr. Over 3 years profit has grown 29.6% a year on average. That is 13.6% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹52.0 Cr.

For the full year, FY26 profit was ₹185 Cr (+24.2% on the year before).

Why profit moved: revenue changed +22.2% on a year earlier and the margin moved +0.0 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed +19.4% and revenue +19.7%. Profit and revenue are moving at about the same pace.

Corona Remedies Ltd reported ₹441 Cr of revenue in the Sep 2026 quarter, +22.2% on the same quarter a year earlier. That is the 7th quarter in a row with growth on the year before. Over 3 years it has grown 16.6% a year on average. The last full year, FY26, came in at ₹1,403 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹1,558 Cr.

FY26 revenue was ₹1,403 Cr, +17.3% on the year before.

Recent pace: the last four quarters grew +19.7% on average, against 16.6% a year over the longer run, so this year is growing faster than its own long-run rate.

Corona Remedies Ltd's operating margin was 22.0% in the Sep 2026 quarter, about the same as the same quarter a year ago. Across 4 years it has been between 14.0% and 21.0%. The latest quarter is above every full year in that period.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

In the latest quarter it moved +0.0 percentage points on the same quarter a year ago.

Why the margin moved: operating margin changed +0.0 percentage points on the year while gross margin changed +0.8 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

Over the last 3 years, 136% of Corona Remedies Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹229 Cr of operating cash against ₹185 Cr of profit. After ₹179 Cr of spending on assets, ₹50.0 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 136% of profit came in as cash: the cash cycle got 48 days shorter between FY23 and FY26, so cash that used to wait in the business now arrives sooner.

What to look at next: the bigger use of cash is spending on new assets, at 5.3× depreciation over three years. The next section checks what that spending is building.

Corona Remedies Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 7 days in FY26, down from 55 days in FY23. It spent ₹550 Cr on assets over the last 3 years. Customers take 38 days to pay, and stock sits for 175 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹1,403 Cr, each day of that cycle ties up about ₹3.8 Cr, so roughly ₹27.0 Cr is tied up in the business at any time.

FY26: customers took 38 days to pay and stock sat for 175 days, about 5.8 months of sales sitting as stock, for a full cycle of 7 days, shorter than FY23's 55.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 175 days. Customers pay about 38 days after that. Suppliers are paid at 206 days. Together that makes the 7-day cycle.

Spending on assets: ₹550 Cr over the last 3 years, against ₹103 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹143 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Corona Remedies Ltd's P/E is 68.0×, about the highest it has ever been. Its usual P/E (the middle reading) is 57.9×, over 11 months of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹33.85.

Why the multiple is where it is: over the past year earnings per share moved +23.9% while the price moved +77.6%. The price did better than earnings, which pushed the multiple up within its own range.

In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple.

Corona Remedies Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 8 quarters of 1 measure, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Corona Remedies Ltd earned a ROCE of 33% in FY26. That is up from a low of 25% in FY24. Its return on capital used (ROIC) is 13.7 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 13.2% net margin and 1.16× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY26): a 13.2% net margin × 1.16× asset turnover × 1.61× leverage (assets divided by equity) ≈ 24.7% on equity. The margin does its share; borrowing is a big part of it.

The key test, return on capital used minus the cost of capital: 25.7% − 12.0% = +13.7 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value.

Corona Remedies Ltd has total debt of ₹115 Cr against shareholder equity of ₹805 Cr as of Sep 2026, so its debt is 0.14× its equity, which is very little. Year by year, that ratio went from 0.33 in FY24 to 0.22 in FY26. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

No group of Corona Remedies Ltd's owners changed its stake by a full percentage point over the last 4 quarters. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

For Corona Remedies Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

58.0 out of 100, rank 14 of 44 in Pharma - Formulators, with 73% of the evidence available.

Corona Remedies Ltd scores 58.0 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 14. There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone.

The three scored parts add up to the total exactly: 25.2 + 25.3 + 7.5 = 58 (no relative-strength reading this week; its 20 points are shared across the other three). This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Corona Remedies ranks 14 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 58.0 out of 100.

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Pharma - Formulators, all 44 compared on one page.

Corona Remedies is the 22nd largest of 44 Pharma - Formulators companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Alembic Pharmaceuticals, ERIS Lifesciences and Natco Pharma. Just below it: Marksans Pharma, Akums Drugs & Pharmaceuticals and Strides Pharma Science.

Pharma - Formulators companies close in size

19. Alembic Pharmaceuticals Ltd ₹17,553 crore
20. ERIS Lifesciences Ltd ₹17,029 crore
21. Natco Pharma Ltd ₹15,348 crore
22. Corona Remedies Ltd ₹14,593 crore
23. Marksans Pharma Ltd ₹14,242 crore
24. Akums Drugs & Pharmaceuticals Ltd ₹11,734 crore
25. Strides Pharma Science Ltd ₹9,851 crore

All 44 Pharma - Formulators companies, largest first

Companies close in size in other industries

459. Bayer CropScience Ltd ₹14,636 crore · Pesticides/Agrochemicals
460. Clean Max Enviro Energy Solutions Ltd ₹14,612 crore · Power Generation & Supply
461. Corona Remedies Ltd ₹14,593 crore
462. Jindal Saw Ltd ₹14,584 crore · DI Pipes/Saw Pipes
463. Shaily Engineering Plastics Ltd ₹14,580 crore · Plastics - Plastic & Plastic Products

Sector Alpha, written by code from the published numbers. Data as of 6 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.